<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="case-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Clin Case Rep</journal-id>
<journal-id journal-id-type="iso-abbrev">Clin Case Rep</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)2050-0904</journal-id>
<journal-id journal-id-type="publisher-id">CCR3</journal-id>
<journal-title-group>
<journal-title>Clinical Case Reports</journal-title>
</journal-title-group>
<issn pub-type="epub">2050-0904</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28469864</article-id>
<article-id pub-id-type="pmc">5412812</article-id>
<article-id pub-id-type="doi">10.1002/ccr3.834</article-id>
<article-id pub-id-type="publisher-id">CCR3834</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Case Report</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Case Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>
<italic><styled-content style="fixed-case">FMR</styled-content>1</italic> premutation with Prader–Willi phenotype and fragile X‐associated tremor/ataxia syndrome</article-title>
<alt-title alt-title-type="left-running-head">V. Martínez‐Cerdeño <italic>et al</italic>.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" id="ccr3834-cr-0001">
<name>
<surname>Martínez‐Cerdeño</surname>
<given-names>Verónica</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9613-3603</contrib-id>
<address>
<email>vmartinezcerdeno@ucdavis.edu</email>
</address>
<xref ref-type="aff" rid="ccr3834-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="ccr3834-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="ccr3834-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ccr3834-cr-0002">
<name>
<surname>Lechpammer</surname>
<given-names>Mirna</given-names>
</name>
<xref ref-type="aff" rid="ccr3834-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ccr3834-cr-0003">
<name>
<surname>Noctor</surname>
<given-names>Stephen</given-names>
</name>
<xref ref-type="aff" rid="ccr3834-aff-0003">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="ccr3834-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ccr3834-cr-0004">
<name>
<surname>Ariza</surname>
<given-names>Jeanelle</given-names>
</name>
<xref ref-type="aff" rid="ccr3834-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="ccr3834-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ccr3834-cr-0005">
<name>
<surname>Hagerman</surname>
<given-names>Paul</given-names>
</name>
<xref ref-type="aff" rid="ccr3834-aff-0005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ccr3834-cr-0006">
<name>
<surname>Hagerman</surname>
<given-names>Randi</given-names>
</name>
<xref ref-type="aff" rid="ccr3834-aff-0003">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="ccr3834-aff-0006">
<sup>6</sup>
</xref>
</contrib>
</contrib-group>
<aff id="ccr3834-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology and Laboratory Medicine</named-content>
<institution>UC Davis Medical Center</institution>
<named-content content-type="city">Sacramento</named-content>
<named-content content-type="country-part">CA</named-content>
<country country="US">USA</country>
</aff>
<aff id="ccr3834-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Institute for Pediatric Regenerative Medicine and Shriners Hospitals for Children Northern California</institution>
<named-content content-type="city">Sacramento</named-content>
<named-content content-type="country-part">CA</named-content>
<country country="US">USA</country>
</aff>
<aff id="ccr3834-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">MIND Institute</named-content>
<institution>UC Davis Medical Center</institution>
<named-content content-type="city">Sacramento</named-content>
<named-content content-type="country-part">CA</named-content>
<country country="US">USA</country>
</aff>
<aff id="ccr3834-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry and Behavioral Sciences</named-content>
<institution>UC Davis Medical Center</institution>
<named-content content-type="city">Sacramento</named-content>
<named-content content-type="country-part">CA</named-content>
<country country="US">USA</country>
</aff>
<aff id="ccr3834-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Biochemistry and Molecular Medicine</named-content>
<institution>UC Davis Medical Center</institution>
<named-content content-type="city">Sacramento</named-content>
<named-content content-type="country-part">CA</named-content>
<country country="US">USA</country>
</aff>
<aff id="ccr3834-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Pediatrics</named-content>
<institution>UC Davis Medical Center</institution>
<named-content content-type="city">Sacramento</named-content>
<named-content content-type="country-part">CA</named-content>
<country country="US">USA</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>
Verónica Martínez‐Cerdeño, 2425 Stockton Boulevard, Sacramento 95817, CA, USA. Tel: (916) 453‐2163; Fax: (916) 453‐2288; E‐mail: <email>vmartinezcerdeno@ucdavis.edu</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>23</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<month>5</month>
<year>2017</year>
</pub-date>
<volume>5</volume>
<issue>5</issue>
<issue-id pub-id-type="doi">10.1002/ccr3.2017.5.issue-5</issue-id>
<fpage>625</fpage>
<lpage>629</lpage>
<history>
<date date-type="received">
<day>11</day>
<month>12</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>07</day>
<month>11</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>04</day>
<month>1</month>
<year>2017</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 John Wiley & Sons Ltd. <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2017 The Authors. <italic>Clinical Case Reports</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement>
<license license-type="creativeCommonsBy">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:CCR3-5-625.pdf" xlink:type="simple"></self-uri>
<abstract id="ccr3834-abs-0001">
<title>Key Clinical Message</title>
<p>This is a report of <italic><styled-content style="fixed-case">FMR</styled-content>1</italic> premutation with Prader–Willi phenotype (<styled-content style="fixed-case">PWP</styled-content>) and <styled-content style="fixed-case">FXTAS</styled-content>. Although the <styled-content style="fixed-case">PWP</styled-content> is common in fragile X syndrome (<styled-content style="fixed-case">FXS</styled-content>), it has never been described in someone with the premutation. The patient presented intranuclear inclusions, severe obesity, hyperphagia, and <styled-content style="fixed-case">ADHD</styled-content> symptoms, typical of the <styled-content style="fixed-case">PWP</styled-content> in <styled-content style="fixed-case">FXS</styled-content>. In addition, the autopsy revealed multiple architectural cortical abnormalities.</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="ccr3834-kwd-0001">
<italic><styled-content style="fixed-case">FMR</styled-content>1</italic>
</kwd>
<kwd id="ccr3834-kwd-0002">Fragile X</kwd>
<kwd id="ccr3834-kwd-0003">FXTAS</kwd>
<kwd id="ccr3834-kwd-0004">inclusions</kwd>
<kwd id="ccr3834-kwd-0005">neurons</kwd>
<kwd id="ccr3834-kwd-0006">Prader–Willi</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>National Institute of Health</funding-source>
<award-id>HD036071</award-id>
<award-id>HD040661</award-id>
<award-id>MH101188</award-id>
<award-id>MH094681</award-id>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>Shiners Hospitals</funding-source>
</award-group>
</funding-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="0"></table-count>
<page-count count="5"></page-count>
<word-count count="2566"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>ccr3834</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>May 2017</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.9 mode:remove_FC converted:18.05.2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="ccr3834-sec-0001">
<title>Introduction</title>
<p>The Prader–Willi phenotype (PWP) of the fragile X syndrome (FXS) has been described at least in 27 patients <xref ref-type="ref" rid="ccr3834-bib-0001">1</xref>, <xref ref-type="ref" rid="ccr3834-bib-0002">2</xref>, <xref ref-type="ref" rid="ccr3834-bib-0003">3</xref>. These patients suffered from obesity starting in childhood together with lack of satiation and hyperphagia. They also demonstrated severe behavioral problems and intellectual disability with social deficits. Patients with FXS and PWP suffered more severe behavioral problems with a higher rate of social deficits compared to FXS without the PWP <xref ref-type="ref" rid="ccr3834-bib-0003">3</xref>. FXS is a neurodevelopmental syndrome with a CGG expansion of more than 200 repetitions in the <italic>FMR1</italic> gene, while some older carriers of this expansion (55–200 repetitions) suffer from the neurodegenerative fragile X‐associated tremor/ataxia syndrome (FXTAS). <italic>FMR1</italic> protein (FMRP) interacts with the mRNA translation regulators CYFIP1 and CYFIP2 <xref ref-type="ref" rid="ccr3834-bib-0004">4</xref>, <xref ref-type="ref" rid="ccr3834-bib-0005">5</xref>. Interestingly, <italic>CYFIP1</italic> is localized to the region critical for Prader‐Willi Syndrome (PWS) at 15q <xref ref-type="ref" rid="ccr3834-bib-0006">6</xref>. While <italic>FMR1</italic> messenger RNA (mRNA) and FMRP are lacking in FXS, FMRP levels are normal or mildly reduced while mRNA is increased in FXTAS.</p>
</sec>
<sec id="ccr3834-sec-0002">
<title>Case Report</title>
<p>FXTAS is a late‐onset neurodegenerative disorder associated with premutation alleles (55–200 CGG repeats) of the <italic>FMR1</italic> gene <xref ref-type="ref" rid="ccr3834-bib-0007">7</xref>, <xref ref-type="ref" rid="ccr3834-bib-0008">8</xref>. FXTAS is characterized by the presence of ubiquitin‐positive inclusions in neurons and astrocytes. FXTAS symptoms include cerebellar ataxia, tremor, cognitive deficits, peripheral neuropathy, autonomic dysfunction, and psychiatric involvement.</p>
<p>Here, we present a male subject with features of PWP that carried an <italic>FMR1</italic> premutation with 73 CGG repeats and an FMRP level of 89.5% of normal. Unfortunately, samples for molecular analysis were not collected. In the future, it will be important to obtain whole‐exome sequencing of patients with FXTAS who also present with PWP. He was described as hyperactive with learning problems in school. Although he was impulsive with attention deficit disorder association (ADHD) symptoms, he never utilized stimulant medication. He had significant learning problems in school and did not graduate from high school although he received his degree years later. Anxiety was severe in childhood, and he chronically chewed on his nails. He began to gain weight at 6 years of age related to compulsive eating and lack of satiation after meals. He went to a weight control program camp at age of 8 years, but he continued to gain weight. He would eat until he threw up between 7 and 9 years old. Obesity was a chronic and significant problem for him and he underwent gastric (bypass) surgery in his forties when he weighed 400 pounds. Following surgery, he suffered indigestion and diarrhea, but he did loose over 100 lbs. He had his first myocardial infarction in his mid‐30s, suffered from multiple myocardial infarctions during his 40s, and had coronary bypass surgery in his late 40s after multiple stents had been placed. He was a smoker for many years until his early 40s. He also developed gait ataxia and began using a cane in his late 40s and 50s. He did not have a tremor but experienced handwriting problems. He was hypertensive, and experienced chronic pain in his 40s, which included migraine headaches and leg pain, the latter thought to be secondary to a neuropathy. He suffered from depression but was not treated with antidepressants. He died at age 55 in a car accident. His mother, an obligate carrier, suffered from features of FXTAS including gait ataxia leading to use of a wheelchair, neuropathic pain, and cognitive decline. His sister is a premutation carrier, and she has a son with fragile X syndrome and autism (Fig. <xref ref-type="fig" rid="ccr3834-fig-0001">1</xref>).</p>
<fig fig-type="Figure" id="ccr3834-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>Patient's photograph.</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="CCR3-5-625-g001"></graphic>
</fig>
<p>The autopsy findings were remarkable for multiple architectural cortical abnormalities including bilateral abnormal gyration or gyri crowding; mild enlargement of the left lateral ventricle; broad thinning of the cortex, more prominent in rostral cortex (3 mm); thin corpus callosum, mainly at its posterior level (0.4–0.5 mm); and a left small inferior olive (Fig. <xref ref-type="fig" rid="ccr3834-fig-0002">2</xref>). The cerebral cortex presented with increased thickness, cellularity and abnormal undulation of the molecular layer, and a relative decrease in cortical thickness in layers II‐VI with marked decrease in number of cortical neurons (Fig. <xref ref-type="fig" rid="ccr3834-fig-0003">3</xref>). These changes have been described previously as characteristic of PWS <xref ref-type="ref" rid="ccr3834-bib-0009">9</xref>. However, other dysmorphic features of the brain described in PWS, such as cerebellar coning, were not found. The cortex presented with marked neuronal depletion, with residual neurons often exhibiting abnormal morphology. Prominent gliosis was observed and highlighted with GFAP and Olig2. Numerous Iba1‐positive microglia were observed. There were no beta‐amyloid plaques or tau‐associated pathology and no iron accumulation. White matter was hypercellular and populated by microglia (highlighted by Iba‐1) and reactive astrocytes (GFAP+). In addition, intraparenchymal blood had perivascular clearing and hyalinized walls. The ependyma appeared focally denudated with underlying subependymal gliosis. There was a loss of pyramidal neurons in the CA1 with associated gliosis. Some neurons exhibited abnormal perikaryon accumulation of SMI312 that also highlighted abnormally thickened axons. The cerebellar cortex possessed a thickened molecular layer, and cerebellar Purkinje cells manifested moderate patchy depletion. The dentate nucleus had prominent acutely ischemic red neurons. There were also findings consistent with hypoxic/ischemic injury of the brain such as small vessel disease that is usually seen in patients with hypertension or diabetes.</p>
<fig fig-type="Figure" id="ccr3834-fig-0002" orientation="portrait" position="float" xml:lang="en">
<label>Figure 2</label>
<caption>
<p>Thick coronal sections of the brain. (A) Thin corpus callosum and expanded left lateral ventricle. (B and B’) Thin cortex and thin <styled-content style="fixed-case">II</styled-content>‐<styled-content style="fixed-case">VI</styled-content> layers when compared to the thickened layer I. (C) Small left inferior olive. (D) Gyri crowding (arrowhead) in the medial region of the occipital lobe. (F) Abnormal gyrification (arrowhead) in the lateral frontal lobe. Calibration bars: A: 6 mm, B: 4 mm, C. 2 mm, D–E: 1 cm.</p>
</caption>
<graphic id="nlm-graphic-5" xlink:href="CCR3-5-625-g002"></graphic>
</fig>
<fig fig-type="Figure" id="ccr3834-fig-0003" orientation="portrait" position="float" xml:lang="en">
<label>Figure 3</label>
<caption>
<p>(A) H&amp;E demonstrating abnormal undulation and thickened layer I in the temporal cortex. (B) Loss of NeuN+ pyramidal cells in the <styled-content style="fixed-case">CA</styled-content>1 of the hippocampus. (C) Abnormally large number of Iba1 + microglial cells with an activated morphology within subcortical white matter. (D) Ubiquitin+ intranuclear inclusions within astrocyes and (E) within a pyramidal cell in the prefrontal cortex. Calibration bars: A: 200 <italic>μ</italic>m, B: 50 <italic>μ</italic>m, C. 25 <italic>μ</italic>m, D‐E: 10 <italic>μ</italic>m.</p>
</caption>
<graphic id="nlm-graphic-7" xlink:href="CCR3-5-625-g003"></graphic>
</fig>
<p>Ubiquitin‐positive intranuclear inclusions were present in astrocytes and neurons, consistent with a diagnosis of FXTAS. Cerebral and cerebellar cortices presented with intranuclear inclusions in 14% of cells, while the hippocampus had 3% in the molecular layer, 14% in the pyramidal layer, and 11% in the granular layer. Intranuclear inclusions in astrocytes were massive, occupying up to 80% of the nucleus, while in neurons, the inclusions were smaller and about the size of the nucleolus (Fig. <xref ref-type="fig" rid="ccr3834-fig-0003">3</xref>D and E).</p>
</sec>
<sec id="ccr3834-sec-0003">
<title>Discussion</title>
<p>This is the first case linking the presence of the <italic>FMR1</italic> premutation to PWP. This case presented with severe obesity, severe hyperphagia, lack of satiation, and ADHD symptoms, typical of the PWP described in FXS <xref ref-type="ref" rid="ccr3834-bib-0003">3</xref>. The premutation involvement manifested with FXTAS symptoms that began in his 40s, unusually early for the symptoms of neuropathy and ataxia. He meets criteria of FXTAS based on the presence of the intranuclear inclusions throughout his brain, in addition to symptoms of ataxia and neuropathy <xref ref-type="ref" rid="ccr3834-bib-0010">10</xref>. In addition, the autopsy findings included multiple architectural cortical abnormalities that may be related to migration problems <xref ref-type="ref" rid="ccr3834-bib-0011">11</xref>. These problems are likely additive to his history of ADHD and learning problems in childhood. Such learning/developmental (ADHD, social deficits, and anxiety/depression) problems occur in approximately 15–30% of premutation males <xref ref-type="ref" rid="ccr3834-bib-0012">12</xref>, <xref ref-type="ref" rid="ccr3834-bib-0013">13</xref>. He also experienced early onset of FXTAS symptoms, which may be more likely to occur if developmental problems are experienced in childhood such as ASD. At 55 years, the number and size of the inclusions were very high compared to that of other premutation carriers previously described <xref ref-type="ref" rid="ccr3834-bib-0014">14</xref>, <xref ref-type="ref" rid="ccr3834-bib-0015">15</xref>, <xref ref-type="ref" rid="ccr3834-bib-0016">16</xref>. It is likely that his recurrent hypoxia from repeated myocardial infarctions and his hypertension increased white matter disease and that exacerbated the progression of FXTAS. It may also be possible that the presence of the PWP and depression added increased oxidative stress that may also have exacerbated the progression of FXTAS <xref ref-type="ref" rid="ccr3834-bib-0017">17</xref>, <xref ref-type="ref" rid="ccr3834-bib-0018">18</xref>. Other cases of the PWP have only been reported with patients with FXS <xref ref-type="ref" rid="ccr3834-bib-0002">2</xref>, <xref ref-type="ref" rid="ccr3834-bib-0003">3</xref>. However, his mildly low level of FMRP could have led to predisposition toward the PWP. FMRP controls <italic>CYFIP</italic> which is located in the 15q deletion region of PWS and a previous report demonstrated downregulation of <italic>CYFIP 1</italic> in the PWP in FXS <xref ref-type="ref" rid="ccr3834-bib-0003">3</xref>. Clinically he did not meet criteria for PWS because his learning problems were not severe or typical for PWS and he had frequent vomiting in childhood which does not happen in those with PWS. There may be more cases of the PWP in premutation carriers particularly those with low levels of FMRP combined with developmental and eating problems at an early age as reported here <xref ref-type="ref" rid="ccr3834-bib-0005">5</xref>.</p>
<p>The interaction between an <italic>FMR1</italic> mutation and the PWP is worthy of further exploration.</p>
</sec>
<sec id="ccr3834-sec-0005">
<title>Conflict of Interest</title>
<p>The funding source had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
</sec>
<sec id="ccr3834-sec-0006">
<title>Authorship</title>
<p>VMC: designed the study, acquired data, analyzed and interpreted data, made figures, wrote the manuscript, and supervised study. ML: analyzed and interpreted data. JA: acquired data. SN and PH: reviewed the manuscript for intellectual content. RH: designed the study, acquired data, analyzed and interpreted data, reviewed the manuscript for intellectual content, and supervised the study.</p>
</sec>
</body>
<back>
<ack id="ccr3834-sec-0004">
<title>Acknowledgments</title>
<p>This work was supported by the National Institute of Health – HD036071 (Randi J. Hagerman), HD040661 (Paul J. Hagerman), MH101188 (Stephen Noctor), MH094681 (V. Martínez‐Cerdeño), and Shriners Hospitals (V. Martínez‐Cerdeño).</p>
</ack>
<ref-list content-type="cited-references" id="ccr3834-bibl-0001">
<title>References</title>
<ref id="ccr3834-bib-0001">
<label>1</label>
<mixed-citation id="ccr3834-cit-0001" publication-type="journal">
<string-name>
<surname>Fryns</surname>, <given-names>J. P.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Haspeslagh</surname>
</string-name>, <string-name>
<given-names>A. M.</given-names>
<surname>Dereymaeker</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Volcke</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Van den Berghe</surname>
</string-name>. <year>1987</year>
<article-title>A peculiar subphenotype in the fra(X) syndrome: extreme obesity‐short stature‐stubby hands and feet‐diffuse hyperpigmentation. Further evidence of disturbed hypothalamic function in the fra(X) syndrome?</article-title>
<source/>Clin. Genet.
<volume>32</volume>:<fpage>388</fpage>–<lpage>392</lpage>.<pub-id pub-id-type="pmid">3436088</pub-id></mixed-citation>
</ref>
<ref id="ccr3834-bib-0002">
<label>2</label>
<mixed-citation id="ccr3834-cit-0002" publication-type="journal">
<string-name>
<surname>Schrander‐Stumpel</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>W.J.</given-names>
<surname>Gerver</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Meyer</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Engelen</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Mulder</surname>
</string-name>, and <string-name>
<given-names>J. P.</given-names>
<surname>Fryns</surname>
</string-name>. <year>1994</year>
<article-title>Prader‐Willi‐like phenotype in fragile X syndrome</article-title>. <source/>Clin. Gen.
<volume>45</volume>:<fpage>175</fpage>–<lpage>180</lpage>.</mixed-citation>
</ref>
<ref id="ccr3834-bib-0003">
<label>3</label>
<mixed-citation id="ccr3834-cit-0003" publication-type="journal">
<string-name>
<surname>Nowicki</surname>, <given-names>S. T.</given-names>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Tassone</surname>
</string-name>, <string-name>
<given-names>M. Y.</given-names>
<surname>Ono</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Ferranti</surname>
</string-name>, <string-name>
<given-names>M. F.</given-names>
<surname>Croquette</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Goodlin‐Jones</surname>
</string-name>, and <string-name>
<given-names>R. J.</given-names>
<surname>Hagerman</surname>
</string-name>. <year>2007</year>
<article-title>The Prader‐Willi phenotype of fragile X syndrome</article-title>. <source/>J. Dev. Behav. Pediatr.
<volume>28</volume>:<fpage>133</fpage>–<lpage>138</lpage>.<pub-id pub-id-type="pmid">17435464</pub-id></mixed-citation>
</ref>
<ref id="ccr3834-bib-0004">
<label>4</label>
<mixed-citation id="ccr3834-cit-0004" publication-type="journal">
<string-name>
<surname>Bardoni</surname>, <given-names>B.</given-names>
</string-name>, and <string-name>
<given-names>J. L.</given-names>
<surname>Mandel</surname>
</string-name>. <year>2002</year>
<article-title>Advances in understanding of fragile X pathogenesis and FMRP function, and in identification of X linked mental retardation genes</article-title>. <source/>Curr. Opin. Genet. Dev.
<volume>12</volume>:<fpage>284</fpage>–<lpage>293</lpage>.<pub-id pub-id-type="pmid">12076671</pub-id></mixed-citation>
</ref>
<ref id="ccr3834-bib-0005">
<label>5</label>
<mixed-citation id="ccr3834-cit-0005" publication-type="journal">
<string-name>
<surname>Schenck</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Bardoni</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Langmann</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Harden</surname>
</string-name>, <string-name>
<given-names>J. L.</given-names>
<surname>Mandel</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Giangrande</surname>
</string-name>. <year>2003</year>
<article-title>CYFIP/Sra‐1 controls neuronal connectivity in Drosophila and links the Rac1 GTPase pathway to the fragile X protein</article-title>. <source/>Neuron
<volume>38</volume>:<fpage>887</fpage>–<lpage>898</lpage>.<pub-id pub-id-type="pmid">12818175</pub-id></mixed-citation>
</ref>
<ref id="ccr3834-bib-0006">
<label>6</label>
<mixed-citation id="ccr3834-cit-0006" publication-type="journal">
<string-name>
<surname>Chai</surname>, <given-names>J. H.</given-names>
</string-name>, <string-name>
<given-names>D.P.</given-names>
<surname>Locke</surname>
</string-name>, <string-name>
<given-names>J. M.</given-names>
<surname>Greally</surname>
</string-name>, <string-name>
<given-names>J. H.</given-names>
<surname>Knoll</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Ohta</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Dunai</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Yavor</surname>
</string-name>, et al. <year>2003</year>
<article-title>Identification of four highly conserved genes between breakpoint hotspots BP1 and BP2 of the Prader‐Willi/Angelman syndromes deletion region that have undergone evolutionary transposition mediated by flanking duplicons</article-title>. <source/>Am. J. Hum. Genet.
<volume>73</volume>:<fpage>898</fpage>–<lpage>925</lpage>.<pub-id pub-id-type="pmid">14508708</pub-id></mixed-citation>
</ref>
<ref id="ccr3834-bib-0007">
<label>7</label>
<mixed-citation id="ccr3834-cit-0007" publication-type="journal">
<string-name>
<surname>Hagerman</surname>, <given-names>P. J.</given-names>
</string-name>
<year>2012</year>
<article-title>Current gaps in understanding the molecular basis of FXTAS</article-title>. <source/>Tremor. Other Hyperkinet. Mov. (N Y)
<volume>2</volume>:<fpage>pii: tre‐02‐63‐375‐2</fpage>.</mixed-citation>
</ref>
<ref id="ccr3834-bib-0008">
<label>8</label>
<mixed-citation id="ccr3834-cit-0008" publication-type="journal">
<string-name>
<surname>Hagerman</surname>, <given-names>R. J.</given-names>
</string-name>, <string-name>
<given-names>D.A.</given-names>
<surname>Hall</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Coffey</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Leehey</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Bourgeois</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Gould</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Zhang</surname>
</string-name>, et al. <year>2008</year>
<article-title>Treatment of fragile X‐associated tremor ataxia syndrome (FXTAS) and related neurological problems</article-title>. <source/>Clin. Interv. Aging
<volume>3</volume>:<fpage>251</fpage>–<lpage>262</lpage>.<pub-id pub-id-type="pmid">18686748</pub-id></mixed-citation>
</ref>
<ref id="ccr3834-bib-0009">
<label>9</label>
<mixed-citation id="ccr3834-cit-0009" publication-type="journal">
<string-name>
<surname>Stevenson</surname>, <given-names>D. A.</given-names>
</string-name>, <string-name>
<given-names>T.M.</given-names>
<surname>Anaya</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Clayton‐Smith</surname>
</string-name>, <string-name>
<given-names>B. D.</given-names>
<surname>Hall</surname>
</string-name>, <string-name>
<given-names>M. I.</given-names>
<surname>Van Allen</surname>
</string-name>, <string-name>
<given-names>R. T.</given-names>
<surname>Zori</surname>
</string-name>, <string-name>
<given-names>E. H.</given-names>
<surname>Zackai</surname>
</string-name>, et al. <year>2004</year>
<article-title>Unexpected death and critical illness in Prader‐Willi syndrome: report of ten individuals</article-title>. <source/>Am. J. Med. Genet. A
<volume>124A</volume>:<fpage>158</fpage>–<lpage>164</lpage>.<pub-id pub-id-type="pmid">14699614</pub-id></mixed-citation>
</ref>
<ref id="ccr3834-bib-0010">
<label>10</label>
<mixed-citation id="ccr3834-cit-0010" publication-type="journal">
<string-name>
<surname>Hagerman</surname>, <given-names>R.</given-names>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Hagerman</surname>
</string-name>. <year>2013</year>
<article-title>The other face of the fragile X gene. Advances in clinical and molecular understanding of the FMR1 premutation and FXTAS</article-title>. <source/>Lancet Neurol.
<volume>12</volume>:<fpage>786</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="pmid">23867198</pub-id></mixed-citation>
</ref>
<ref id="ccr3834-bib-0011">
<label>11</label>
<mixed-citation id="ccr3834-cit-0011" publication-type="journal">
<string-name>
<surname>Cunningham</surname>, <given-names>C. L.</given-names>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Martinez Cerdeno</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Navarro Porras</surname>
</string-name>, <string-name>
<given-names>A. N.</given-names>
<surname>Prakash</surname>
</string-name>, <string-name>
<given-names>J. M.</given-names>
<surname>Angelastro</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Willemsen</surname>
</string-name>, <string-name>
<given-names>P. J.</given-names>
<surname>Hagerman</surname>
</string-name>, et al. <year>2011</year>
<article-title>Premutation CGG‐repeat expansion of the Fmr1 gene impairs mouse neocortical development</article-title>. <source/>Hum. Mol. Genet.
<volume>20</volume>:<fpage>64</fpage>–<lpage>79</lpage>.<pub-id pub-id-type="pmid">20935171</pub-id></mixed-citation>
</ref>
<ref id="ccr3834-bib-0012">
<label>12</label>
<mixed-citation id="ccr3834-cit-0012" publication-type="journal">
<string-name>
<surname>Farzin</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Perry</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Hessl</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Loesch</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Cohen</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Bacalman</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Gane</surname>
</string-name>, et al. <year>2006</year>
<article-title>Autism spectrum disorders and attention‐deficit/hyperactivity disorder in boys with the fragile X premutation</article-title>. <source/>J. Dev. Behav. Pediatr.
<volume>27</volume>:<fpage>S137</fpage>–<lpage>S144</lpage>.<pub-id pub-id-type="pmid">16685180</pub-id></mixed-citation>
</ref>
<ref id="ccr3834-bib-0013">
<label>13</label>
<mixed-citation id="ccr3834-cit-0013" publication-type="journal">
<string-name>
<surname>Chonchaiya</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Au</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Schneider</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Hessl</surname>
</string-name>, <string-name>
<given-names>S. W.</given-names>
<surname>Harris</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Laird</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Mu</surname>
</string-name>, et al. <year>2012</year>
<article-title>Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co‐morbid autism spectrum disorder</article-title>. <source/>Hum. Genet.
<volume>131</volume>:<fpage>581</fpage>–<lpage>589</lpage>.<pub-id pub-id-type="pmid">22001913</pub-id></mixed-citation>
</ref>
<ref id="ccr3834-bib-0014">
<label>14</label>
<mixed-citation id="ccr3834-cit-0014" publication-type="journal">
<string-name>
<surname>Greco</surname>, <given-names>C. M.</given-names>
</string-name>, <string-name>
<given-names>R.F.</given-names>
<surname>Berman</surname>
</string-name>, <string-name>
<given-names>R. M.</given-names>
<surname>Martin</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Tassone</surname>
</string-name>, <string-name>
<given-names>P. H.</given-names>
<surname>Schwartz</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Chang</surname>
</string-name>, <string-name>
<given-names>B. D.</given-names>
<surname>Trapp</surname>
</string-name>, et al. <year>2006</year>
<article-title>Neuropathology of fragile X‐associated tremor/ataxia syndrome (FXTAS)</article-title>. <source/>Brain
<volume>129</volume>:<fpage>243</fpage>–<lpage>255</lpage>.<pub-id pub-id-type="pmid">16332642</pub-id></mixed-citation>
</ref>
<ref id="ccr3834-bib-0015">
<label>15</label>
<mixed-citation id="ccr3834-cit-0015" publication-type="journal">
<string-name>
<surname>Greco</surname>, <given-names>C. M.</given-names>
</string-name>, <string-name>
<given-names>R.J.</given-names>
<surname>Hagerman</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Tassone</surname>
</string-name>, <string-name>
<given-names>A. E.</given-names>
<surname>Chudley</surname>
</string-name>, <string-name>
<given-names>M. R.</given-names>
<surname>Del Bigio</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Jacquemont</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Leehey</surname>
</string-name>, et al. <year>2002</year>
<article-title>Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers</article-title>. <source/>Brain
<volume>125</volume>:<fpage>1760</fpage>–<lpage>1771</lpage>.<pub-id pub-id-type="pmid">12135967</pub-id></mixed-citation>
</ref>
<ref id="ccr3834-bib-0016">
<label>16</label>
<mixed-citation id="ccr3834-cit-0016" publication-type="journal">
<string-name>
<surname>Martinez‐Cerdeno</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Lechpammer</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Lott</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Schneider</surname>
</string-name>, and <string-name>
<given-names>R.</given-names>
<surname>Hagerman</surname>
</string-name>. <year>2015</year>
<article-title>Fragile X‐associated tremor/Ataxia syndrome in a man in his 30s</article-title>. <source/>JAMA Neurol.
<volume>72</volume>:<fpage>1070</fpage>–<lpage>1073</lpage>.<pub-id pub-id-type="pmid">26368352</pub-id></mixed-citation>
</ref>
<ref id="ccr3834-bib-0017">
<label>17</label>
<mixed-citation id="ccr3834-cit-0017" publication-type="journal">
<string-name>
<surname>Smaga</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Niedzielska</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Gawlik</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Moniczewski</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Krzek</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Przegalinski</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Pera</surname>
</string-name>, et al. <year>2015</year>
<article-title>Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism</article-title>. <source/>Pharmacol. Rep.
<volume>67</volume>:<fpage>569</fpage>–<lpage>580</lpage>.<pub-id pub-id-type="pmid">25933971</pub-id></mixed-citation>
</ref>
<ref id="ccr3834-bib-0018">
<label>18</label>
<mixed-citation id="ccr3834-cit-0018" publication-type="journal">
<string-name>
<surname>Anichini</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Lotti</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Longini</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Proietti</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Felici</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Perrone</surname>
</string-name>, and <string-name>
<given-names>G.</given-names>
<surname>Buonocore</surname>
</string-name>. <year>2012</year>
<article-title>Antioxidant effects of potassium ascorbate with ribose therapy in a case with Prader Willi Syndrome</article-title>. <source/>Dis. Markers
<volume>33</volume>:<fpage>179</fpage>–<lpage>183</lpage>.<pub-id pub-id-type="pmid">22960339</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>